background past year signifies progress made inhibit neovascular tumor site cut nutrient supply growth metastasis howe mani proteinspeptid disadvantage poor static short halflif uncertain target bail chemin modify use overcome disadvantage polyethylene glycolmodifi approve unit state fda purpose studi obtain novel antiangiogen chondroitin sulfate cspeptid nanoparticles concur office antineovascular accept mater method cesar synths character use nuclear magnet reason spectroscopy transmits electron microscopy partial size zeta potent analyze studi mtt migrate tube format chick chorioallanto membrane assay lisa surface plasma bioimag pharmacokinet also result could selfassembl stable nanoparticles aqueous solute significantly enhance active explicit prolong concur c effect proteinpeptid modify display good therapy 